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ABSTRACT 
Atypical femoral fractures, which display characteristics of brittle material failure, have 
been associated with potent remodeling suppression drugs.  Given the millions of 
individuals treated with this class of drugs it is likely that other factors play a role in these 
fractures.  Some evidence suggests concomitant use of corticosteroids may contribute to 
the pathogenesis although data in this area is lacking.  The goal of this study was to 
assess the combined role of bisphosphonates and dexamethasone on bone mechanical 
properties.  Skeletally mature beagle dogs were either untreated controls, or treated with 
zoledronic acid (ZOL), dexamethasone (DEX), or ZOL + DEX.  Zoledronic acid (0.06 
mg/kg) was given monthly via IV infusion for 9 months.  DEX (5 mg) was administered 
daily for one week during each of the last three months of the 9 month experiment.  Ribs 
were harvested and assessed for bone geometry, mechanical properties, and 
remodeling rate (n=3-6 specimens per group).  DEX significantly suppressed intracortical 
remodeling compared to vehicle controls while both ZOL and the combination of 
DEX+ZOL nearly abolished intracortical remodeling.   ZOL treatment resulted in 
significantly lower bone toughness, determined from 3-point bending tests, compared to 
all other treatment groups while the toughness in ZOL+DEX animals was identical to 
those of untreated controls. These findings suggest not only that short-courses of 
dexamethasone do not adversely affect toughness in the setting of bisphosphonates, 
they actually reverse the adverse effects of its treatment.  Understanding the mechanism 
for this tissue-level effect could lead to novels approaches for reducing the risk of 
atypical femoral fractures. 
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INTRODUCTION 
Atypical femoral fractures have been associated with potent remodeling suppression 
pharmaceutical drugs such as bisphosphonates [1].  Although a definitive causal link 
between the pharmaceutical agents and these fractures does not exist, several reports 
provide intriguing data regarding the proposed association [2-7]. The mechanism 
underlying these atypical femoral fractures remains unclear although if anti-remodeling 
agents do in fact play a role it is likely that tissue-level changes related to low bone 
remodeling contribute.  What is clear about atypical femoral fractures is that they are 
catastrophic and debilitating [1].   
Given the millions of individuals treated with anti-remodeling agents, the rarity of 
atypical femoral fractures suggests they are multi-factorial.  The 2010 American Society 
for Bone and Mineral Research task force report on fractures identified glucocorticoid 
treatment as one potential co-factor [1].  Chronic high dose glucocorticoid treatment has 
well-established negative effects including increased osteoclast and decreased 
osteoblast activity, induction of osteocyte apoptosis, loss of bone mass, and reductions 
in mechanical properties [8].  Although bisphosphonates are approved for reducing 
fracture risk associated with glucocorticoid-induced osteoporosis [9], they produce their 
beneficial effect in this setting by suppressing bone loss and thus maintaining bone 
mass.  The effects of bisphosphonates on material properties, those independent of 
bone mass, in the setting of concomitant glucocorticoid treatment have not been 
extensively studied [10].   
Pre-clinical data demonstrate bisphosphonates reduce bone toughness, the 
ability of the bone material to absorb energy prior to fracture [11-16].  Reduced 
toughness is analogous to increased brittleness and thus these data are consistent with 
the fracture characteristics of atypical femoral fractures.  Recently, our laboratory 
undertook a study focused on a condition known as osteonecrosis of the jaw in which we 
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treated animals with a combined of bisphosphonates and glucocorticoids [17].  Using 
material saved from this experiment, the aim of this study was to test the hypothesis that 
the combination of zoledronic acid and dexamethasone would significantly reduce bone 
toughness more than either treatment alone. 
 
MATERIALS AND METHODS 
Animals 
Twenty-four skeletally mature female beagles (~ 1-2 years old) were purchased from 
Marshall Farms USA (North Rose, NY) and housed throughout the experiment in 
environmentally controlled rooms at Indiana University School of Medicine’s AAALAC 
accredited facility.  All animal procedures were approved prior to the study by the IU 
School of Medicine Animal Care and Use Committee. 
 
Experimental Design 
Following two weeks of acclimatization, animals were assigned to untreated control 
(CON; n=6), zoledronic acid (ZOL; n=6), dexamethasone (DEX; n=6) or zoledronic acid 
plus dexamethasone (ZOL+DEX; n=6) treatment groups. The primary goal of this study 
was to investigate the combined effects of ZOL and DEX on oral wound healing  [17], 
thus ZOL was administered via IV infusion at a dose of 0.06 mg/kg (40 mL total volume 
over 15 minutes), which corresponds to the dose used in cancer patients, adjusted on a 
mg/kg basis [18].    ZOL was infused every 2 weeks, roughly twice as frequently as used 
clinically, in order to maximize drug exposure during the experimental period.  
Dexamethasone was given via daily oral dosing (5 mg) for the first seven days of the 7th, 
8th, and 9th months of the experiment.  This dosing was based on a modified version of a 
low-dose protocol used clinically in multiple myeloma pateints [19].  
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 All animals were administered calcein (5 mg/kg, intravenous) using a 2-12-2-5 
schedule, meaning it was administered on two consecutive days, 12 days were allowed 
to pass, injected for another two consecutive days, and then 5 days passed prior to 
euthanasia.  After 9 months animals were euthanized by intravenous administration of 
sodium pentobarbital and the right and left 9th rib were dissected free and placed in 70% 
ethanol and frozen PBS soaked gauze, respectively. Bones from all animals were 
available for histology (n=6/group) but bones for mechanical testing were only saved for 
a subset (n=3) of both control and dexamethasone groups.    The rib was chosen 
because it has traditionally shown consistent alterations in mechanical properties 
associated with bisphosphonate-treatment [11,15]. 
 
Peripheral Quantitative Computed Tomography (pQCT) 
Volumetric bone density and geometry were quantified using a Norland Stratec XCT 
Research SA+ pQCT (Stratec Electronics, Birkenfeld, Germany).  Specimens were cut 
to 40 mm in length and a single scan at the mid-point was conducted using a voxel size 
of 0.07 x 0.07 x 0.50 mm. Total bone mineral content (BMC, mg/mm), total volumetric 
bone mineral density (vBMD, mg/ cm3), bone area (BA, mm2), periosteal circumference, 
cortical thickness, and cross-sectional moment of inertia (CSMI, mm4) were obtained 
using standard scanner software and segmentation algorithms (Cortbd mode with a 
threshold of 710 mg/cm3) to separate cortical bone from marrow.  Bone diameter was 
measured using digital calipers.  Diameter and CSMI values were calculated in the plane 
perpendicular to the axis of three-point bending. 
 
Biomechanical Testing 
Three-point bending was conducted in accordance with our previously described method 
[11]. Briefly, bones were thawed to room temperature in saline and then placed on a 
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three-point bending fixture (bottom support span = 25 mm) with the convex rib surface 
facing up. Specimens were loaded to failure at a displacement rate of 20 mm/minute, 
and data were collected at 10 Hz. Structural mechanical properties, ultimate load, 
stiffness, displacement (pre-yield, post-yield, and total), and energy absorption (pre-
yield, post-yield, and total) were determined from the load–deformation curves using 
standard definitions [20]. Material-level properties, ultimate stress, modulus, and 
toughness (pre-yield, post-yield, and total), were estimated by normalizing the structural 
parameters using standard equations that include bone diameter and CSMI [20]. 
 
Histology 
Ribs were processed for assessment of fluorochrome labels using standard methods of 
undecalcified histology [21]. Two serial semi-thin sections (80–100 µm) were cut 
approximately 5 mm apart using a diamond wire saw. Fluorochrome labels were 
assessed using an analysis system (Bioquant OSTEO 7.20.10; Bioquant Image 
Analysis, Nashville, TN) attached to a microscope equipped with an ultraviolet light 
source. Dynamic histomorphometric measures of the intracortical bone envelope was 
made on one section per animal using methods previously published and in accordance 
with recommended standards [22,23]. 
 
Statistics 
Statistical tests were performed using SAS software (SAS Institute, Inc.).  Histological 
parameters were compared among groups using one-way ANOVA with Fisher’s 
protected least significant difference (pLSD) post-hoc tests.  Due to unequal and small 
sample sizes among groups for geometry and mechanical testing parameters, data were 
assessed using Kruskal Wallis non-parametric tests followed by Mann-Whitney tests to 
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determine group differences. For all tests, p < 0.05 was considered to be statistically 
significant. 
 
RESULTS 
Material-level estimates of toughness, the ability of the material to absorb energy, were 
significantly lower in ZOL-treated animals compared to vehicle controls (Figure 1).  
These effects were driven by significant differences in post-yield toughness with no 
significant difference among groups in pre-yield toughness.  The negative effects of ZOL 
on total and post-yield toughness were abolished in animals treated with both 
ZOL+DEX, which had levels of toughness significantly higher than ZOL and statistically 
similar to VEH animals (Figure 1). There was no significant difference among groups for 
structural-level energy to fracture (Figure 1) indicating that the alterations in geometry 
with ZOL were sufficient to maintain whole-bone energy absorption.   
 
There was no significant treatment effect on whole bone stiffness or material-level 
modulus (Table 1).  While there was no difference among groups in ultimate load, the 
material-level strength (ultimate stress) was significantly higher in both ZOL treated 
groups compared to DEX-treatment alone (Table 1).  Pre-yield displacement was similar 
among groups while post-yield displacement was significantly lower in ZOL compared to 
both VEH and DEX; the combination of ZOL+DEX returned post-yield displacement to 
VEH-level values.   
 
Mid-diaphysis cortical BMC, volumetric BMD cortical bone area, and cortical thickness 
were all significantly higher in both ZOL-treated groups compared to vehicle control 
(Table 2).  There was no significant difference among groups for periosteal 
circumference or cross-sectional moment of inertia. 
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Intracortical labeled osteon number and bone formation rate were both significantly 
lower in DEX-treated animals compared to control (Table 3).  Labeled osteon number in 
ZOL and ZOL+DEX groups was 98% lower than control.  The lack of double labeled 
osteons negated the calculation of bone formation rate in the ZOL and DEX+ZOL 
groups.  
 
DISCUSSION 
The current study provides evidence that bisphosphonate-induced reductions in 
toughness, which have been consistently shown in multiple studies [11-16], can be 
overcome with in vivo treatment.  Using a short-course dexamethasone protocol, one 
that is consistent with what is used clinically in some situations [19], the reductions in 
toughness brought about by zoledronate treatment were completely abolished.  The 
effect of dexamethasone in the absence of zoledronate treatment was unimpressive, 
although the low number of samples (n=3) in this group likely contributed to the lack of 
statistical significance.  However, when combined with zoledronate, dexamethasone 
raised toughness to values that were in line with untreated controls and significantly 
different than ZOL-treatment alone.  We interpret these data as evidence that 
dexamethasone is interacting uniquely in bone that has been exposed to 
bisphosphonate. 
 The underlying mechanism for dexamethasone’s reversal of zoledronate-induced 
toughness reduction is unclear.  Previous work has shown that glucocorticoid treatment 
significantly reduces the modulus surrounding the osteocyte perilacunar matrix in 
trabecular bone of ovariectomized rats [10].   This is consistent with our current results in 
which dexamethasone non-significantly reduces the estimated modulus (calculated from 
a stress/strain curve) relative to animals treated with zoledronate alone.  The perilacunar 
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matrix plays an important role in determining the tissue-level properties of bone 
[10,24,25].  Reductions in perilacunar modulus could be expected to lower the strain 
concentrations around the lacunae and reduce crack propagation through the matrix and 
effectively toughening the bone. 
 Glucocorticoids have well-documented adverse effects on bone cells, bone 
mass, and mechanical properties [8].  The majority of these data are derived from 
chronic, high-dose treatment.  The effects of short-course dosing such as those used in 
the current experiment have not been explored with respect to skeletal properties yet 
evidence exists showing dose-dependent effects on osteocytes in cortical bone [26].  It 
is not clear if the results of the current study are specific to low-dose treatment, or 
whether even higher doses when combined with the potent anti-remodeling effects of 
ZOL would produce similar effects.  The anti-remodeling effect of zoledronate effectively 
abolishes the enhanced osteoclast activity normally induced by dexamethasone and is 
the basis for its efficacy in glucocorticoid-induced bone disease [8,9].  It is assumed that 
this reduction in bone loss is the basis for reduced fractures with bisphosphonates in 
glucocorticoid-treated patients.  The current data raise the possibility that when 
combined with bisphosphonates, glucocorticoids exert mechanically-beneficial 
modifications of material-level properties that are independent of bone mass. 
 Although glucocorticoid treatment has been suggested as a potential co-factor for 
atypical femoral fractures [1], data to support such a link remain equivocal.  Several 
reports have documented that between 8 and 30% of patients with atypical sub-
trochanteric fractures were either on or had been on glucocorticoid treatment in the past 
year [2,3,27].    These cross-sectional studies are limited – but at face value certainly do 
not suggest a strong link.  On the other hand, the results of this current study would 
suggest those on glucocorticoid treatment should actually be protected from these types 
fractures that have characteristics of brittle material failure.  It is important to note that 
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our data do not address how the duration or dose of bisphosphonate treatment would 
affect the ability of glucocorticoids to reverse the effect, or if the effects of glucocorticoids 
are similar at higher doses, such as consistent, high-dose treatment often used clinically. 
Previous work has consistently documented reduced bone toughness in 
bisphosphonate-treated dogs [11-16].  These experiments have utilized oral 
bisphosphonates at doses at and above those used clinically for treatment of post-
menopausal osteoporosis.  The current work shows similar results with intravenous 
zoledronate, albeit at doses that exceed those used even in cancer patients.  The 
proposed mechanisms for reduced toughness with alendronate are related to its 
suppression of remodeling.  Thus the findings in the current study with zoledronate are 
not unexpected given that IV zoledronate suppresses remodeling more rapidly and 
dramatically compared to oral alendronate [22]. 
 The results of this experiment should be considered within the context of some 
limitations.  First, our study utilized intact female beagles and thus the bisphosphonates 
were given in an animal with normal remodeling as opposed to estrogen-deficient high 
bone remodeling.  Secondly, we used doses that far-exceeded those used clinically 
even for cancer patients.  As the reductions in toughness in this study are consistent 
with those from previous studies that used clinically relevant dosing of alendronate [11], 
it is unlikely that high doses played a major role in the findings. Although the concept of 
reduced mechanical properties in bisphosphonate treated animals is consistent with 
atypical femoral fractures, our study utilized ribs while the clinically relevant site is the 
proximal femur.  Whether similar beneficial effects of DEX treatment would be observed 
at the femur in a similar model is unclear and unfortunately femora from this experiment 
were not saved.  Finally, as mechanical property assessment was not the original focus 
of the study the sample size was not powered for such analysis with two groups having 
six specimens and the other two having only three  This may have produced 
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underpowered analyses for some mechanical parameters although the effect on 
toughness was sufficiently large to allow detection even with this limited sample size.  
 In conclusion we show that the reductions in toughness brought about by 
zoledronate treatment in dogs can be completely abolished using short-course 
dexamethasone treatment.  These results could have significant implications given the 
emergence of atypical femoral fractures as a rare but significant side effect associated 
with remodeling suppression. 
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Figure Legend 
 
Figure 1.  Structural (A-C) and material (D-F) properties of rib as determined by 3 point 
bending.  There was no significant difference among groups for whole bone energy to 
fracture (p = 0.09), pre-yield energy (p = 0.93) or post-yield energy (p = 0.07).  The 
material-level equivalent, toughness, was significantly different among groups for both 
total toughness (p = 0.01) and post-yield toughness (p = 0.01) but not pre-yield 
toughness (p = 0.71).  Point plots represent individual test values.  P < 0.05 versus VEH 
(*), DEX (^), and ZOL ($). 
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Table 1: Bone mechanical properties assessed by 3 point bending 
 
 
All data presented as median (minimum – maximum). p < 0.05 vs (*) control, (∧) DEX. 
 
  
 
  
 Control  
(n=3) 
DEX  
(n=3) 
ZOL  
(n=6) 
ZOL + DEX 
(n=6) 
p value 
Ultimate force, N 133 
(83-219) 
192 
(168 – 205) 
206 
(162 – 249) 
205 
(166-254) 
0.487 
Stiffness, N/mm 225 
(143-243) 
361 
(328 – 367) 
237 
(175 – 261) 
219 
(93 – 296) 
0.051 
Pre-yield 
displacement, mm 
0.41 
(0.36 – 0.48) 
0.36 
(0.08 – 0.38) 
0.22 
(0.18 – 0.56) 
0.22 
(0.13 – 0.53) 
0.719 
Post-yield 
displacement, mm 
5.7 
(3.7 – 7.1) 
4.6 
(3.4 – 4.7) 
2.7 *^ 
(1.3 – 3.8) 
3.6 
(2.9 – 6.4) 
0.034 
Ultimate stress, 
MPa 
140 
(105 – 168) 
144 
(143-144) 
200 ^ 
(149 – 274) 
207 *^ 
(178 – 239) 
0.012 
Modulus, MPa 4392 
(3458 – 4404) 
3975 
(3823 – 4808) 
6140 
(5152 – 8993) 
5723 
(2192 – 6517) 
0.053 
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Table 2: Rib cortical bone density and geometry 
 
 
All data presented as median (minimum – maximum). p < 0.05 vs (*) control. 
 
  
 Control  
(n=3) 
DEX  
(n=3) 
ZOL  
(n=6) 
ZOL + DEX 
(n=6) 
p value 
vBMD, mg/cm3 1105 
(1091-1106) 
1105 
(1132 – 1195) 
1186 * 
(1173-1224) 
1174  * 
(1144 – 1197) 
0.027 
BMC, mg/mm 8.25 
(6.49 – 8.28) 
9.5 
(9.46-10.29) 
11.46 * 
(9.65 – 12.68) 
10.52 * 
(9.86-12.42) 
0.016 
Bone area, mm2 7.49 
(5.88- 7.56) 
8.36 
(7.95 – 8.99) 
9.67  * 
(8.22-10.77) 
9.06  * 
(8.37 – 10.49) 
0.029 
Periosteal 
circumference, mm 
11.27 
(10.29 – 12.6) 
13.16 
(12.18 – 13.86) 
11.69 
(11.34 – 13.72) 
12.46 
(11.9 – 12.88) 
0.129 
Cortical thickness, 
mm 
0.68 
(0.66 – 0.76) 
0.73 
(0.67 – 0.76) 
0.98 * 
(0.87 – 1.12) 
0.87 * 
(0.76 – 1.00) 
0.011 
CSMI, mm4 17.1 
(10.8 – 23.4) 
30.3 
(22.7 – 31.9) 
21.2 
(18.6 – 32.0) 
26.4 
(21.8 – 29.9) 
0.172 
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Table 3: Dynamic histomorphometry data of intra-cortical rib remodeling 
 Control  
(n=6) 
DEX  
(n=6) 
ZOL  
(n=6) 
ZOL + DEX 
(n=6) 
Labeled osteon 
number, #/mm2 
2.88 ± 0.51 1.26 ± 0.41 * 0.07 ± 0.02 *∧ 0.05 ± 0.02 *∧ 
Bone formation rate, 
%/year 
23.7 ± 4.6 14.6 ± 3.6 * NA NA 
Data presented as mean ± SE. p < 0.05 vs (*) control or (∧) DEX.  NA means there were 
no double label osteons in any animal and thus bone formation rate could not be 
calculated. 
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